Propoxyphene use while Breastfeeding
Drugs containing Propoxyphene: Darvon, Darvocet-N 50, Darvocet-N 100, Darvocet A500, Balacet, Wygesic, Propacet 100, Trycet, PP-Cap, Darvon-N, Show all 14 »PC-CAP, Darvon Compound-65, Darvon Compound 32, Propoxyphene Compound 65
Propoxyphene Levels and Effects while Breastfeeding
Summary of Use during Lactation
Maternal use of oral narcotics during breastfeeding can cause infant drowsiness, central nervous system depression and even death. Newborn infants seem to be particularly sensitive to the effects of even small dosages of propoxyphene may be particularly prone to causing these effects. Propoxyphene should be avoided during breastfeeding.
Propoxyphene is metabolized to active norpropoxyphene (25%) and to several inactive metabolites. Norpropoxyphene has a 30 to 36 hour half-life. The oral bioavailability of norpropoxyphene is unknown. Propoxyphene is available in 2 salt forms: 65 mg of the hydrochloride form is equivalent to 100 mg of the napsylate.
Maternal Levels. Six breastfeeding mothers, 5 in the first few days postcesarean section and 1 at 10 months postpartum were given oral propoxyphene hydrochloride 130 mg once then 65 mg every 4 hours for 16 hours for a cumulative dose of 390 mg. Breastmilk propoxyphene was measured at 1, 3, 5, 7, and 9 hours after the last dose. Propoxyphene peak levels occurred at 3 hours while norpropoxyphene levels remained fairly constant. An average propoxyphene and norpropoxyphene milk level over the 8-hour collection period was calculated for each patient and varied substantially among patients (range 24 to 210 mcg/L for propoxyphene and 54 to 606 mcg/L for norpropoxyphene). Norpropoxyphene had a longer maternal plasma half-life and thus accumulated in breastmilk more so than propoxyphene. Greater breastmilk production was associated with higher milk levels of both propoxyphene and norpropoxyphene. Using the highest average milk propoxyphene level in this study, an exclusively breastfed infant would receive 32 mcg/kg daily of propoxyphene and 91 mcg/kg daily of norpropoxyphene, equivalent to about 2% of the maternal weight-adjusted dosage.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
In a case-control study of 12 breastfed term newborns with unexplained episodes of apnea, bradycardia or cyanosis during the first week of life, maternal oral propoxyphene use was determined to be the probable cause. A higher proportion of newborns with episodes, 83 compared to 31%, had mothers using opiates, including propoxyphene, for postpartum analgesia. The mean number of doses taken was also higher with mothers of affected newborns taking a mean of 10 doses (range 4 to 22) compared to 5 doses (range 1 to 13) in the control group.
A fullterm breastfed infant had mild hypotonia and nursing poorly at 10 days of age; the infant had not regained her birth weight by this time. By 7 days later, the mother had less milk and stopped nursing. The infant's mother had been prescribed 6 capsules daily of propoxyphene 30 mg plus acetaminophen 500 mg for the first 10 days postpartum. Hair samples from the infant were positive for propoxyphene and norpropoxyphene and were higher than the mother's hair sample concentrations. Propoxyphene was probably the cause of the adverse reactions in the infant.
All adverse reactions in breastfed infants reported in France between January 1985 and June 2011 were compiled by a French pharmacovigilance center. Of 174 reports, propoxyphene was reported to cause adverse reactions in 11 infants and to be one of the drugs most often suspected in serious adverse reactions. Reactions included hypotonia, apnea, respiratory distress, bradycardia, constipation and weight loss.
Effects on Lactation and Breastmilk
Narcotics can increase serum prolactin. However, the prolactin level in a mother with established lactation may not affect her ability to breastfeed.
Alternate Drugs to Consider
1. Sachs HC and the American Academy of Pediatrics committee on Drugs. The transfer of drugs and therapeutics into human breast milk: An update on selected topics. Pediatrics. 2013;132:e796-809. PMID: 23979084
2. Kunka RL, Venkataramanan R, Stern RM et al. Excretion of propoxyphene and norpropoxyphene in breast milk. Clin Pharmacol Ther. 1984;35:675-80. PMID: 6713779
3. Kunka RL, Yong CL, Ladik CF et al. Liquid chromatographic determination of propoxyphene and norpropoxyphene in plasma and breast milk. J Pharm Sci. 1985;74:103-4. PMID: 3981406
4. Naumburg EG, Meny RG. Breast milk opioids and neonatal apnea. Am J Dis Child. 1988;142:11-2. Letter. PMID: 3341293
5. Rigourd V, Amirouche A, Tasseau A et al. Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008;32:787-9. PMID: 19021937
6. Soussan C, Gouraud A, Portolan G et al. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. Eur J Clin Pharmacol. 2014;70:1361-6. PMID: 25183382
7. Tolis G, Dent R, Guyda H. Opiates, prolactin, and the dopamine receptor. J Clin Endocrinol Metab. 1978;47:200-3. PMID: 263291
CAS Registry Number
LactMed Record Number
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.